EDGE
21.2.2021 17:53:06 CET | Business Wire | Press release
SIGN4L, a dynamic provider of agile and adaptive electronic warfare and intelligence (EW&I) solutions, today launched two state-of-the-art solutions that are set to offer a tactical advantage in the missions of tomorrow. V-Protect, a radio frequency (RF) communication jamming system, and NavControl-G, a specialised counter-drone capability, are well positioned to become game-changers in shaping favourable outcomes in an increasingly digitalised defence landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210221005031/en/
The solutions were unveiled at the EDGE pavilion at the ongoing International Defence Exhibition and Conference (IDEX 2021) that runs until 25 February at the Abu Dhabi National Exhibition Centre (ADNEC).
V-Protect is an advanced mobile active and reactive high-power jammer system aimed at helping block common terrestrial RF signal technologies as well as portable satcom equipment, spanning radio, walkie-talkie, mobile and Wi-Fi frequencies. Boasting a counter-improvised explosive device (C-IED) and counter-drone measures, the user-friendly model is to be installed in a standard SUV and offers automatic operability by utilizing 16 channels and high emitting power amplifiers to provide support in enhancing protection range and combatting various threats across the frequency domain.
NavControl-G is a sophisticated transmitter unit designed to help prevent unmanned aerial vehicles (UAVs) from trespassing into specific locations. To help safeguard a sensitive area, the system can emulate GPS signals to generate position and timing inaccuracies, thereby taking control of non-cooperating unmanned vehicles. Encased in a shock-proof container, the system can be seamlessly integrated across multiple configurations - either in fixed locations or deployed on the field when required.
Waleid Al Mesmari, Vice President of Program Management for the Electronic Warfare & Intelligence cluster at EDGE, said: “Electronic warfare and intelligence make up the backbone of modern defence and security systems. SIGN4L is at the frontlines in pioneering breakthrough technologies that help our clients expand their options in a rapidly changing world. By assisting our clients with the management of their complex security and performance requirements, our latest solutions are prime examples of our agile offerings at work that focus energy to obscure, neutralise and attack adversaries.”
SIGN4L brings a startup ethos to designing and producing state-of-art open-architecture digital and RF-based security products and services for governments and businesses in the region. The company has implemented a rigorous cycle of threat analysis, research, and development to monitor, analyse and counter emerging risks. SIGN4L is part of the Electronic Warfare & Intelligence cluster at EDGE, an advanced technology group that ranks among the top 25 military suppliers in the world.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210221005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom